ebola-virus

Documents about ebola-virus

• Experimental Vaccine for Prevention of Ebola Virus Infection#414372ClinicalTrials.gov
• Whose fears count? Legitimacy, trust and viral outbreak responses after COVID-19#393156PLOS
• REVIVE (Response to the Ebola Virus Vaccine)#353345ClinicalTrials.gov
• Fear, stigma and Uncertainty: The short and long-term effects of Ebola on survivors, affected families, and community in Bundibugyo, Western Uganda#672183PLOS
• Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines#1322958ClinicalTrials.gov
• Multiple Treatments for Ebola Virus Disease (EVD)#1430704ClinicalTrials.gov
• Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)#18697ClinicalTrials.gov
• R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease#917776ClinicalTrials.gov
• EBOla Post-Exposure Prophylaxis#245567ClinicalTrials.gov
• Representation of Trauma in Selected Literary Works on Ebola Virus Disease#1068364University of Ibadan Institutional Repository
• Ebola and Marburg Virus Vaccines#901254ClinicalTrials.gov
• Solidarity/Tokomeza Ebola Trial#1033262ClinicalTrials.gov
• Ebola virus and Sudan virus infection in humans: a comparison to inform vaccine research and development#642677Europe PMC
• Open Study of the Duration of Immunity After Vaccination With GamEvac#1295834ClinicalTrials.gov
• Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response#148782ClinicalTrials.gov
• Partnership for Research on Ebola VACcinations#1409234ClinicalTrials.gov
• Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen#1162058ClinicalTrials.gov
• GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen#1164763ClinicalTrials.gov
• Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)#1394594ClinicalTrials.gov
• Evaluating an Ebola and a Marburg Vaccine in Uganda#1032766ClinicalTrials.gov
• An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease#1433194ClinicalTrials.gov
• A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV#261336ClinicalTrials.gov
• A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants#901804ClinicalTrials.gov
• Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon#287392ClinicalTrials.gov
• Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up#872629ClinicalTrials.gov
• Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo#1196758ClinicalTrials.gov
• Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)#913398ClinicalTrials.gov
• A Study of a New Vaccine Against Two Types of Ebola#1420984ClinicalTrials.gov
• Efficacy of Favipiravir Against Ebola (JIKI)#217068ClinicalTrials.gov
• Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)#261362ClinicalTrials.gov
• Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus#1349565ClinicalTrials.gov
• Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine#1213887ClinicalTrials.gov
• Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects#1075511ClinicalTrials.gov
• Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo#1376142ClinicalTrials.gov
• A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease#1497727ClinicalTrials.gov
• Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda#968427ClinicalTrials.gov
• Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC#459971ClinicalTrials.gov
• Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment#860756ClinicalTrials.gov
• EBOVAC-Salone Extension#180202ClinicalTrials.gov
• Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)#146254ClinicalTrials.gov
• WHO emergency guidance on the use of licensed Ebola virus vaccine during Bundibugyo virus disease outbreaks,...#237670World Health Organization
• Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults#1280629ClinicalTrials.gov
• Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP#1087759ClinicalTrials.gov
• A smart phone based expert system for airport screening of infectious diseases : test case with the Ebola virus symptoms#938651SU+ Digital Repository
• A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.#424244ClinicalTrials.gov
• Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)#832388ClinicalTrials.gov
• The mental health professional at the feet of the Ebola virus: individual treatment and global mental challenges#250234HAL (France)
• Ebola at a critical juncture: preparedness must outpace transmission#349389WHO IRIS
• Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)#152516ClinicalTrials.gov
• A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.#882001ClinicalTrials.gov